NEW YORK, NY / ACCESSWIRE / February 3, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

GPS Shareholders Click Here: https://www.zlk.com/pslra-1/the-gap-inc-lawsuit-submission-form?prid=36230&wire=1
NEO Shareholders Click Here: https://www.zlk.com/pslra-1/neogenomics-lawsuit-submission-form?prid=36230&wire=1
ARBK Shareholders Click Here: https://www.zlk.com/pslra-1/argo-blockchain-lawsuit-submission-form?prid=36230&wire=1

* ADDITIONAL INFORMATION BELOW *

The Gap, Inc. (NYSE:GPS)

GPS Lawsuit on behalf of: investors who purchased November 24, 2021 - July 11, 2022
Lead Plaintiff Deadline : February 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/the-gap-inc-lawsuit-submission-form?prid=36230&wire=1

According to the filed complaint, during the class period, The Gap, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) there were execution missteps in size and assortment at Old Navy related to BODEQUALITY, the Company's size-inclusivity campaign, which were adversely impacting Old Navy's margins and financial results; (2) contrary to the Company's statements, there were inventory risks relating to BODEQUALITY that were adversely affecting the Company's operations; and as a result (3) the Company's statements during the class period about the historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of the Company, and were materially false and misleading and lacked a factual basis.

NeoGenomics, Inc. (NASDAQ:NEO)

NEO Lawsuit on behalf of: investors who purchased February 27, 2020 - April 26, 2022
Lead Plaintiff Deadline : February 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/neogenomics-lawsuit-submission-form?prid=36230&wire=1

According to the filed complaint, during the class period, NeoGenomics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants represented to investors that it had a 'comprehensive menu' of cancer tests with 'every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing,' which positioned the Company as a 'one-stop-shop' for pathologists and gave NeoGenomics 'a competitive advantage' as a 'go-to reference lab with a comprehensive menu for just about any kind of tests that you want to have done in cancer' and (2) defendants represented that NeoGenomics could 'leverage' the supposedly 'fixed cost' structure of its business to improve profitability as revenue increased and touted the Company's 'robust Compliance Program . . . to ensure compliance with the myriad of . . . laws, regulations and governmental guidance applicable to our business.'

Argo Blockchain plc (NASDAQ:ARBK)

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Argo American Depository Shares pursuant and/or traceable to the documents issued in connection with the Company's initial public offering conducted on or about September 23, 2021; and/or (b) Argo securities between September 23, 2021 and October 10, 2022, both dates inclusive.
Lead Plaintiff Deadline : March 27, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/argo-blockchain-lawsuit-submission-form?prid=36230&wire=1

According to the filed complaint, (i) Argo was highly susceptible to and/or suffered from significant capital constraints, electricity and other costs, and network difficulties; (ii) the foregoing issues hampered Argo's ability to mine Bitcoin or Bitcoin equivalents, execute its business strategy, meet its obligations, and operate its Helios facility; (iii) as a result, Argo's business was less sustainable than defendants had led investors to believe; (iv) accordingly, Argo's business and financial prospects were overstated; and (v) as a result, the documents issued in connection with the Company's initial public offering and defendants' public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP